title: [Tuberculosis and infliximab treatment. National surveillance from January 1, 2000, through June 30, 2003].
abstract: OBJECTIVE
  Analysis of the tuberculosis cases reported in France in patients treated with infliximab since its marketing approval, assessment of the effect of changes in the summary of product characteristics and national guidelines.
  
  
  METHODS
  Based on tuberculosis reports from the national post-marketing adverse drug reaction databank of the manufacturer from January 1, 2000 through June 30, 2003, and records from the national multicenter retrospective survey on opportunistic infections with anti-TNFalpha, we analyzed all cases of tuberculosis and the impact of the changes made in December 2000 in the summary of product characteristics and the guidelines on the prevention and management of tuberculosis in patients treated with infliximab published in February 2002.
  
  
  RESULTS
  56 cases of tuberculosis were reported: the median interval before diagnosis was 12 weeks with a median of 3 infusions. The presence of Koch bacilli was confirmed in 32 patients; 29 patients had extrapulmonary or disseminated forms of tuberculosis. The tuberculosis rate among patients treated with infliximab was greater than among the general population and differed significantly by period (p < 0.005).
  
  
  CONCLUSIONS
  Tuberculosis can occur within the first 12 weeks of treatment with infliximab. Information for practitioners must be continued, together with surveillance of the tuberculosis cases in France.
authors.affiliation: Centre régional de pharmacovigilance, Hôpital Pasteur, 30 avenue de la Voie Romaine, BP 69, 06002 Nice. baldin.b@chu-nice.fr
authors.forename: Bernadette
authors.initials: B
authors.lastname: Baldin
authors.forename: Adrien
authors.initials: A
authors.lastname: Dozol
authors.forename: Anne
authors.initials: A
authors.lastname: Spreux
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Chichmanian
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D005602:France / Q000453:epidemiology; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006306:Health Surveys; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D014376:Tuberculosis / Q000453:epidemiology / Q000209:etiology*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005765:Gastrointestinal Agents; D000069285:Infliximab